Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data
- 20 August 2010
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (24), 3866-3871
- https://doi.org/10.1200/jco.2010.28.5031
Abstract
Purpose We previously reported our results with a single-agent arsenic trioxide (ATO) –based regimen in newly diagnosed cases of acute promyelocytic leukemia (APL). The concern remained about the long-term outcome of this well-tolerated regimen. We report our long-term follow-up data on the same cohort. Patients and Methods From January 1998 to December 2004, 72 patients with PML/RARα+ APL were enrolled. All patients were treated with a single-agent ATO regimen. Results Overall 62 (86.1%) achieved a hematologic remission (complete remission). After the initial report, an additional seven patients have relapsed for a total of 13 relapses. There were no additional toxicities to report on follow-up. At a median follow-up 60 months, the 5-year Kaplan-Meier estimate (± SE) of event-free survival, disease-free survival, and overall survival (OS) was 69% ± 5.5%, 80% ± 5.2%, and 74.2% ± 5.2%, respectively. The OS in the good risk group as defined by us remains 100% over this period. Conclusion Single-agent ATO as used in this study in the management of newly diagnosed cases of APL is safe and is associated with durable responses. Results in the low-risk group are comparable to that reported with conventional therapy while additional interventions would probably be required in high-risk cases.Keywords
This publication has 14 references indexed in Scilit:
- How I treat acute promyelocytic leukemiaBlood, 2009
- Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicityBlood, 2006
- Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicityLeukemia, 2006
- Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapyAnnals Of Oncology, 2005
- Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acidBlood, 2005
- Acute Myeloid Leukemia and Acute Promyelocytic LeukemiaHematology-American Society Hematology Education Program, 2003
- United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic LeukemiaJournal of Clinical Oncology, 2001
- Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adultsProceedings of the National Academy of Sciences of the United States of America, 1999
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- The "Retinoic Acid Syndrome" in Acute Promyelocytic LeukemiaAnnals of Internal Medicine, 1992